Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald G Grosset

Showing results (1-10 of 99) with videos related to

Pageof 10
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Role of dopamine transporter imaging in the diagnosis of atypical tremor disordersVicky Marshall, Donald G Grosset
CNS Drugs|December 16, 2014
Medication adherence in patients with Parkinson's diseaseNaveed Malek, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Dopamine transporter imagingAndrew J Lees, Donald G Grosset
Current Opinion in Investigational Drugs (London, England : 2000)|February 27, 2004
GPI-1485 (Guilford)Victoria L Marshall, Donald G Grosset
Lancet (London, England)|June 9, 2004
Pergolide in Parkinson's disease: time for a change?Katherine A Grosset, Donald G Grosset
BMC Neurology|July 20, 2007
Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trialKatherine A Grosset, Donald G Grosset
Clinical Therapeutics|September 23, 2006
Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's diseaseKatherine A Grosset, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|February 19, 2005
Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of lifeKatherine A Grosset, Donald G Grosset
Journal of Experimental Pharmacology|May 18, 2016
Investigational agents in the treatment of Parkinson's disease: focus on safinamideNaveed M Malek, Donald G Grosset
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2008
Timing the initiation of treatment in Parkinson's diseaseDonald G Grosset, Anthony H Schapira
Pageof 10

Showing results (1-10 of 99) with videos related to

Sort By:
Pageof 10
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Role of dopamine transporter imaging in the diagnosis of atypical tremor disordersVicky Marshall, Donald G Grosset
CNS Drugs|December 16, 2014
Medication adherence in patients with Parkinson's diseaseNaveed Malek, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|October 8, 2003
Dopamine transporter imagingAndrew J Lees, Donald G Grosset
Current Opinion in Investigational Drugs (London, England : 2000)|February 27, 2004
GPI-1485 (Guilford)Victoria L Marshall, Donald G Grosset
Lancet (London, England)|June 9, 2004
Pergolide in Parkinson's disease: time for a change?Katherine A Grosset, Donald G Grosset
BMC Neurology|July 20, 2007
Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trialKatherine A Grosset, Donald G Grosset
Clinical Therapeutics|September 23, 2006
Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's diseaseKatherine A Grosset, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|February 19, 2005
Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of lifeKatherine A Grosset, Donald G Grosset
Journal of Experimental Pharmacology|May 18, 2016
Investigational agents in the treatment of Parkinson's disease: focus on safinamideNaveed M Malek, Donald G Grosset
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2008
Timing the initiation of treatment in Parkinson's diseaseDonald G Grosset, Anthony H Schapira
Pageof 10